Literature DB >> 22613932

MicroRNAs as putative mediators of treatment response in prostate cancer.

Fardod O'Kelly1, Laure Marignol, Armelle Meunier, Thomas H Lynch, Antoinette S Perry, Donal Hollywood.   

Abstract

MicroRNAs (miRNAs) are an abundant class of noncoding RNAs that function to regulate post-transcriptional gene expression, predominantly by translational repression. In addition to their role in prostate cancer initiation and progression, recent evidence suggests that miRNAs might also participate in treatment response across a range of therapies including radiation treatment, chemotherapy and androgen suppression. The mechanism of this regulation is thought to be multifactorial and is currently poorly understood. To date, only a small number of studies have examined the functional role of miRNAs in response to prostate cancer treatment. Elucidating the role of miRNAs in treatment response following radiotherapy, chemotherapy and androgen suppression will provide new avenues of investigation for the development of novel therapies for the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613932     DOI: 10.1038/nrurol.2012.104

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  132 in total

1.  Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.

Authors:  Shahana Majid; Altaf A Dar; Sharanjot Saini; Yi Chen; Varahram Shahryari; Jan Liu; Mohd Saif Zaman; Hiroshi Hirata; Soichiro Yamamura; Koji Ueno; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.

Authors:  Alexandre de la Taille; Jacques Irani; Markus Graefen; Felix Chun; Theo de Reijke; Paul Kil; Paolo Gontero; Alain Mottaz; Alexander Haese
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

Review 3.  DNA methylation and gene silencing in cancer.

Authors:  Stephen B Baylin
Journal:  Nat Clin Pract Oncol       Date:  2005-12

4.  A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance.

Authors:  Yuan Wu; Yuzhong Xiao; Xiaofeng Ding; Yiming Zhuo; Peng Ren; Chang Zhou; Jianlin Zhou
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

5.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.

Authors:  Tong Sun; Qianben Wang; Steven Balk; Myles Brown; Gwo-Shu Mary Lee; Philip Kantoff
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

6.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.

Authors:  Dejuan Kong; Yiwei Li; Zhiwei Wang; Sanjeev Banerjee; Aamir Ahmad; Hyeong-Reh Choi Kim; Fazlul H Sarkar
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

9.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.

Authors:  Tao Li; Dong Li; Jianjun Sha; Peng Sun; Yiran Huang
Journal:  Biochem Biophys Res Commun       Date:  2009-03-18       Impact factor: 3.575

10.  miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.

Authors:  Cyrielle Clapé; Vanessa Fritz; Corinne Henriquet; Florence Apparailly; Pedro Luis Fernandez; François Iborra; Christophe Avancès; Martin Villalba; Stéphane Culine; Lluis Fajas
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

View more
  13 in total

Review 1.  Aberrant expression of microRNAs in bladder cancer.

Authors:  Hirofumi Yoshino; Naohiko Seki; Toshihiko Itesako; Takeshi Chiyomaru; Masayuki Nakagawa; Hideki Enokida
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

Review 2.  When Prostate Cancer Circulates in the Bloodstream.

Authors:  Virginie Vlaeminck-Guillem
Journal:  Diagnostics (Basel)       Date:  2015-10-29

3.  MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathway.

Authors:  Jia-Quan Qu; Hong-Mei Yi; Xu Ye; Li-Na Li; Jin-Feng Zhu; Ta Xiao; Li Yuan; Jiao-Yang Li; Yuan-Yuan Wang; Juan Feng; Qiu-Yan He; Shan-Shan Lu; Hong Yi; Zhi-Qiang Xiao
Journal:  Oncotarget       Date:  2015-09-29

4.  A prognostic model for lung adenocarcinoma patient survival with a focus on four miRNAs.

Authors:  Xianqiu Li; Zhaoling An; Peihui Li; Haihua Liu
Journal:  Oncol Lett       Date:  2017-06-27       Impact factor: 2.967

5.  Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer.

Authors:  João Ramalho-Carvalho; Inês Graça; Antonio Gomez; Jorge Oliveira; Rui Henrique; Manel Esteller; Carmen Jerónimo
Journal:  J Hematol Oncol       Date:  2017-02-06       Impact factor: 17.388

6.  Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2).

Authors:  Xiangsheng Li; Zhichao Zhang; Ming Yu; Liqi Li; Guangsheng Du; Weidong Xiao; Hua Yang
Journal:  Int J Mol Sci       Date:  2013-08-06       Impact factor: 5.923

Review 7.  The genomic landscape of prostate cancer.

Authors:  Lien Spans; Liesbeth Clinckemalie; Christine Helsen; Dirk Vanderschueren; Steven Boonen; Evelyne Lerut; Steven Joniau; Frank Claessens
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

8.  miRNA in Prostate Cancer: New Prospects for Old Challenges.

Authors:  Samy M Mekhail; Peter G Yousef; Stephen W Jackinsky; Maria Pasic; George M Yousef
Journal:  EJIFCC       Date:  2014-04-28

Review 9.  MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.

Authors:  Lisa-Maria Schanza; Maximilian Seles; Michael Stotz; Johannes Fosselteder; Georg C Hutterer; Martin Pichler; Verena Stiegelbauer
Journal:  Int J Mol Sci       Date:  2017-11-22       Impact factor: 5.923

Review 10.  Gene suppression approaches to neurodegeneration.

Authors:  Rhia Ghosh; Sarah J Tabrizi
Journal:  Alzheimers Res Ther       Date:  2017-10-05       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.